SCHEMBL5357589

SCHEMBL5357589

CC(=O)n1cc(C=C2C(=O)Nc3ccc(Br)c(C)c32)c2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.64
MEN1 O00255 7/20 0.64
NTRK1 P04629 4/20 0.45
MAP3K5 Q99683 1/20 0.45
MAPT P10636 2/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
NTRK3 Q16288 3/20 0.43
NTRK2 Q16620 3/20 0.43
SYK P43405 2/20 0.43
FCER2 P06734 1/20 0.43
ACHE P22303 1/20 0.43
BRPF1 P55201 1/20 0.42
CREBBP Q92793 1/20 0.42
BRD9 Q9H8M2 1/20 0.42
HDAC6 Q9UBN7 1/20 0.41
AURKA O14965 1/20 0.41
ROCK2 O75116 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7130446 0.85 NTRK1 (0.63) KMT2AMEN1NTRK1MAP3K5MAPT
SCHEMBL7136052 0.85 KMT2A (0.63) KMT2AMEN1NTRK1MAP3K5MAPT
SCHEMBL7132935 0.75 MEN1 (0.56) KMT2AMEN1RETIGF1RKDR
SCHEMBL7131343 0.73 NPC1 (0.56) KMT2AMEN1RETIGF1RRPS6KB1
SCHEMBL7131400 0.73 MEN1 (0.42) KMT2AMEN1RETPIM1KDR
SCHEMBL5369619 0.73 KMT2A (0.60) KMT2AMEN1NTRK1MAP3K5MAPT
SCHEMBL5377025 0.72 RET (0.54) KMT2AMEN1MAPTHDAC6RET
SCHEMBL7134339 0.72 RET (0.45) KMT2AMEN1NTRK1MAPTNTRK3
SCHEMBL5359703 0.72 RET (0.37) KMT2AMEN1NTRK1MAP3K5NTRK3
SCHEMBL5357636 0.72 SYK (0.59) KMT2AMEN1NTRK1MAP3K5NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK KMT2A 4060/4885MEN1 3855/4885NTRK1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.